Kerberan (Clopidogrel)

Clopidogrel irreversibly blocks the platelet P2Y12 ADP receptor, preventing ADP‑driven activation of the GPIIb/IIIa complex. This inhibition stops platelets from aggregating, thereby reducing the formation of arterial clots that can cause heart attacks or strokes.

The dose of Kerberan is individualized by the prescribing clinician based on the patient’s clinical condition, renal function, and concomitant therapies. Healthcare providers determine the appropriate strength and frequency according to current treatment guidelines.

Safety data for clopidogrel in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Kerberan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Kerberan (clopidogrel) is a thienopyridine that provides irreversible P2Y12 inhibition, whereas agents like ticagrelor offer reversible inhibition and a faster onset. Choice of therapy depends on patient risk profile, drug‑drug interaction potential, and clinician preference.

Kerberan tablets should be stored at ambient temperature below 25 °C, in the original container, protected from moisture and direct light. Keep out of reach of children and do not use if the packaging is damaged.

Kerberan is taken orally, usually with or without food, as directed by a healthcare professional. The tablet should be swallowed whole with water and not crushed or chewed unless specifically instructed.

The most serious risks associated with Kerberan include severe or uncontrolled bleeding, thrombotic thrombocytopenic purpura (TTP), and rare hepatic dysfunction. Patients should seek immediate medical attention if they experience unusual bruising, blood in stool or urine, or signs of liver injury.

Kerberan is contraindicated in patients with active pathological bleeding, known hypersensitivity to clopidogrel or any component of the formulation, and in those with severe hepatic impairment. Clinicians should also avoid use in patients taking certain strong CYP2C19 inhibitors without careful assessment.